Arch Intern Med. 2009;169(21):1952–60.PubMedCrossRef 8. Ensrud KE, Blackwell TL, Mangione CC, Schwartz AV, Hanlon JT, Nevitt MC. Central nervous system-active medications and risk for falls
in older women. J Am Geriatr Soc. 2002;50:1629–37.PubMedCrossRef 9. Mendelson WB. The use of sedative/hypnotic medication and its correlation with falling down in the hospital. Sleep. 1996;19(9):698–701.PubMed 10. Liu B, Anderson G, Mittman N, To T, Axcell T, Shear N. Use of selective serotonin-reuptake inhibitors of tricyclic antidepressants and risk of hip fractures in elderly people. Lancet. 1998;351:1303–7.PubMedCrossRef 11. Thapa PB, Gideon P, Cost TW, Milam AB, Ray WA. Antidepressants and the risk of falls among Smad inhibitor nursing home residents. New Engl J Med. 1998;339:875–82.PubMedCrossRef
12. Luukinen H, Koski K, Laippala P, Kivela SL. Predictors for recurrent falls among the home-dwelling elderly. Scand J Prim Health Care. 1995;13:294–9.PubMedCrossRef 13. Verhaeverbeke I, Mets I. Drug-induced orthostatic hypotension in the elderly: avoiding its onset. Drug Saf. 1997;17:105–18.PubMedCrossRef 14. Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in selleck inhibitor older people: a systematic review and meta-analysis. I: psychotropic drugs. J Am Geriatr Soc. 1999;47:30–9.PubMed 15. Bloem BR, Steijns JA, Smits-Engelsman BC. An update on falls. Curr Opin Neurol. 2003;16:15–26.PubMedCrossRef 16. Rudolph U, Crestani F, Benke D, Brunig I, Benson JA, Fritschy J-M, Martin JR, Bluethmann H, Mohler H. Benzodiazepine actions mediated by specific γ-aminobutyric acid A receptor subtypes. Nature. 1999;401:796–800.PubMedCrossRef 17. Hanson SM, Morlock EV, Satyshur KA, Czajkowski C. Structural Racecadotril requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABA(A)) receptor are different. J Med Chem. 2008;51:7243–52.PubMedCrossRef 18. Gibson MJ. Falls in later life. In: Improving the health of older people: a world view. Oxford University Press, Oxford; 1990. p. 296–315.
19. Tanaka M, Suemaru K, Ikegawa Y, Tabuchi N, Araki H. Relationship between the risk of falling and drugs in an academic hospital. Yakugaku Zasshi. 2008;128:1355–61.PubMedCrossRef 20. Yasui M, Kato A, Kanemasa T, Murata S, Nishitomi K, Koike K, Tai N, Shinohara S, Tokomura M, Horiuchi M, Abe K. Pharmacological profiles of benzodiazepinergic hypnotics and correlations with receptor subtypes. Nihon Shinkei Seishin Yakurigaku Zasshi. 2005;25:143–51.PubMed 21. Pascal GG, Shirakawa K. Zolpidem: objectives, strategy and medicinal chemistry. Jpn J Clin Psychopharmacol. 2001;4:93–7. 22. Shirakawa K. Pharmacological profile and clinical effect of zolpidem (Myslee tablets), a hypnotic agent. Nippon Yakurigaku Zasshi. 2002;119:111–8.PubMedCrossRef 23. www.selleckchem.com/products/chir-98014.html Noguchi H, Kitazumi K, Mori M, Shiba T. Binding and neuropharmacological profile of zaleplon, a novel nonbenzodiazepine sedative/hypnotic. Eur J Pharmacol. 2002;434:21–8.